Credit Acceptance Corporation reports Q1 2026 results today after the close, with shorts having spent the past six weeks quietly reducing exposure — yet the stock remains one of the most heavily shorted names in consumer finance heading into the print.
Short sellers have cut their bets meaningfully since mid-March. SI % of free float peaked near 22% in the week of March 18–20, when availability in the lending market was extremely tight — the 52-week tightest, with utilization at 96%. That pressure has since eased. By April 28, SI % FF had pulled back to 17.7%, down 7.3% week-on-week and almost 18% over the past month. Borrow availability has loosened in parallel: utilization has fallen to 71%, and cost to borrow has drifted down to 0.84% from around 1.1% at the April peak. The borrow market is no longer stressed. That said, 17.7% of float short on earnings day is not a cleared position — it's a live, meaningful bet, with an ORTEX short score of 72.2 ranking the stock in the top few percent of the universe for short-side pressure.
Options positioning reinforces the cautious tone. The put/call ratio is running at 3.07, well above its 20-day average of 2.83, and near the top of its 52-week range (52-week high: 3.66). The ratio jumped sharply in the second week of April — from the 1.7 range that had prevailed in late March — and has held elevated ever since. That shift coincides almost exactly with the period when short interest peaked and the stock's one-month run-up began: CACC gained 19% over the past month to close Wednesday at $500.62. Elevated PCR into a strong price rally reads as hedging, not conviction selling — investors protecting gains rather than adding fresh directional shorts.
The Street is thinly covered and divided. Only two analysts are tracking the stock with any recent activity. Stephens & Co. raised their target from $450 to $540 on April 17, keeping an Equal-Weight rating — an acknowledgment of the re-rating but not an outright endorsement. TD Cowen holds a Sell with a $430–470 range of recent targets; the mean analyst target is $481.67, which at Wednesday's close of $500.62 implies the consensus price target is now below the current price by about $19, or -3.8% (flagged: only two analysts tracked, so this mean has limited statistical weight). The stock's PE is 11.0x, having expanded roughly 2.5 turns over 30 days. P/B sits at 2.1x. DTC of 8.1 days means any sharp squeeze would require time to unwind — the borrow is not the tight kind that resolves overnight.
A 10% shareholder — Jill Foss Watson — sold approximately 6,600 shares across multiple tranches on April 21, with combined proceeds around $2.5 million. The 90-day net insider position is positive at just under $20 million in net value bought, so the April selling represents a trim within a broader holding context. At the institutional level, Prescott General Partners, the second-largest holder with 14.3% of shares, added nearly 95,000 shares in Q4 2025 — a meaningful increase. Boston Partners, Dimensional, and Vanguard each added modestly in Q1 2026. Founder Donald Foss's trust holds 19.9% and has been unchanged.
Earnings history matters here. The last confirmed Q3 2025 report on January 30 produced a +15% one-day move and a +14% five-day move. That kind of explosive post-earnings reaction in a heavily shorted, thinly-covered name is exactly why shorts have been trimming into strength — and why the put/call ratio has climbed so sharply. Close peers have had a rough week: BFH fell 7.6% and SYF dropped 4.5%, while ALLY lost 4.2%. CACC itself is down 5% on the week, giving back part of its April gains ahead of the release.
With earnings dropping today, the setup is a stock still sitting on a 17.7% short float, a put/call ratio near its highest level since last autumn, and a $20m institutional buyer active in Q4 — the next few hours test every side of that positioning simultaneously.
See the live data behind this article on ORTEX.
Open CACC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
